- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
A Word from PharmExec
A note from the editors regarding the magazine, webcasts and other activities.
Like everyone, the staff of Pharmaceutical Executive and our parent company MJH Life Sciences is pivoting to address the current needs of our readers and clients.
If you are one of our print subscribers, we realize that if you receive the monthly publication at your workplace, you might not receive it. So we will deliver the digital version/PDF to you via email, if we have your email. Please note that your issues will still be delivered to you via postal mail, and will be awaiting your return to the office. If you wish to change your delivery address, or delivery preference, you can do so via our online subscription form.
If you are a regular webcast viewer, please note they are still the most popular form of learning right now. Our sister brands at LCGC and Spectroscopy are addressing COVID-19 concerns in the lab. Please note, all of our webcasts are available OnDemand, so if you have missed any, you can go back and watch.
More webinars were launched this week to our healthcare audience, including “Managing Lung Cancer Patients Through the COVID-19 Pandemic: What to Know” on the MJH Life Sciences OncLive brand.
The MJH Life Sciences teams also converted two live full-day, multi-speaker CME-accredited meetings to digital formats within a 48 hour time frame, and we now have a virtual format for dinner events or summits, which is particularly important to the pharma companies used to working in-person. You can reach our business development team if you want to discuss.
And, as always, you can reach the editors directly at their emails with news, articles or questions.
Remember to visit us on LinkedIn, Twitter, Instagram or Soundcloud for our latest information, COVID or otherwise.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
